Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma

Caroline E. Nunes-Xavier1,2*, Olaia Aurtenetxe1, Laura Zaldumbide3, Ricardo López-Almaraz4, Asier Erramuzpe5, Jesús M. Cortés5,6, José I. López1,3 and Rafael Pulido1,6,7*

Abstract

Background: Protein tyrosine phosphatases (PTPs) regulate neuronal differentiation and survival, but their expression patterns and functions in human neuroblastoma (NB) are scarcely known. Here, we have investigated the function and expression of the non-receptor PTPN1 on human NB cell lines and human NB tumor samples.

Material/methods: NB tumor samples from 44 patients were analysed by immunohistochemistry using specific antibodies against PTPN1, PTPRH, PTPRZ1, and PTEN. PTPN1 knock-down, cell proliferation and tyrosine phosphorylation analyses, and RT-qPCR mRNA expression was assessed on SH-SY5Y, SMS-KCNR, and IMR-32 human NB cell lines.

Results: Knock-down of PTPN1 in SH-SY5Y NB cells resulted in increased tyrosine phosphorylation and cell proliferation. Retinoic acid-mediated differentiation of NB cell lines did not affect PTPN1 mRNA expression, as compared with other PTPs. Importantly, PTPN1 displayed high expression on NB tumors in association with metastasis and poor prognosis.

Conclusions: Our results identify PTPN1 as a candidate regulator of NB cell growth and a potential NB prognostic biomarker.

Keywords: Neuroblastoma, Neuroblastoma differentiation, Metastatic neuroblastoma, Protein tyrosine phosphatases, PTPN1

Background

Neuroblastoma (NB) constitutes a heterogeneous malignancy arising from sympathetic neural precursor cells from the neural crest. NB is the most common extracranial tumor in children, accounting in its high-risk forms for about 15% of childhood cancer mortality. The majority of NB tumors develop in the adrenal medulla, and, with less frequency, in the paraspinial ganglia from neck, chest, abdomen, and pelvis [1–4]. Unbalanced neuronal differentiation seems to be an important aspect in NB initiation and progression, with many primary and metastatic NB tumors showing spontaneous regression [5, 6]. High-risk NB do not show regression and are currently treated with a combination of chemo- and radio-therapy protocols, autologous stem cell transplant, and surgery, followed by maintenance therapies based on immuno-therapy and retinoic acid (RA) cell differentiating agents. However, high-risk NB are highly malignant and frequently relapse after these combination therapies, rendering a survival lower than 50% of treated children [7, 8]. Improvements in the definition of therapy response biomarkers and in the implementation of more effective targeted therapies are current necessities in the management of high-risk NB patients [9–12].

Tyrosine phosphorylation, executed by protein tyrosine kinases (PTKs), is one of the landmark protein post-translational modifications in human cancer [13]. The receptor tyrosine kinase (RTK) ALK is mutated in NB tumors and in the germline of patients with familial NB [14–16], and ALK plays a major role in the signal transduction mechanism driving NB development, being a major potential target in NB targeted therapy [17, 18]. ALK hyperactivation associates in NB with MYCN gene amplification, the major biomarker for high-risk NB, and...
potentiates MYCN oncogenic activity [19, 20]. In addition, the RTKs TrkA and TrkB are major signalling transducers in the regulation of NB growth, differentiation, and apoptosis, whose expression has been correlated with NB prognosis and regression, and whose therapeutic targeting is also being addressed in NB [21, 22]. These examples illustrate that alterations in the tyrosine phosphorylation cellular status of NB cells are crucial for NB development and progression. However, the regulated protein tyrosine dephosphorylation in NB has been scarcely investigated.

Protein tyrosine phosphatases (PTPs) are the direct executers of dephosphorylation of specific tyrosine residues on specific protein substrates, playing relevant roles in many physiologic and pathologic processes, including those related with the regulation of cell differentiation, transformation, and growth [23–27]. Inhibition of PTPs by vanadium compounds enhances RA-triggered differentiation of NB cells, suggesting an active role for these enzymes in NB cell proliferation and senescence [28]. Moreover, PTP inhibition by vanadate or vanadium compounds courses with induced cell death on NB cell lines, making PTP inhibition a suitable therapeutic option in NB [29].

The non-receptor tyrosine phosphatase PTPN1 (also known as PTP1B) constitutes the paradigm of PTP enzymes and a suitable drug target for cancer and metabolic diseases [30–33], and PTPN1 protein expression has been shown to correlate with metastasis and poor prognosis in several human cancers [34–37]. In this study, analysing human NB tumor samples and cell lines, we have found evidence for PTPN1 as a regulator of NB cell tyrosine phosphorylation and proliferation, and unveiled the association of PTPN1 expression with poor NB patient outcome.

### Methods

**Patients, tissue specimens, and immunohistochemistry**

The characteristics of the patients included in the study have been previously described [38] (Table 1). Histological sections of tissue microarrays (TMAs) or routine paraffin blocks containing the tumor specimens were used for immunohistochemistry (IHC). The antibodies and dilutions used for IHC were: PTEN (1/50, 6H2.1, Merck Millipore), PTPRZ1 (1/50, Clone 12/RPTPb, BD Bioscience), PTPRH (1/500, HPA042300, Sigma-Aldrich), and PTPN1 (1/20, AF1366, R&D). Immunostainings were performed in automated immunostainers (EnVision FLEX, DakoAutostainer Plus; Dako, Glostrup, Denmark) following routine methods. The analysis was done blind by an experienced pathologist (LZ) and performed using a Nikon Eclipse 80i microscope (Tokyo, Japan). The IHC evaluation considered positive (high) those cases with intense nuclear or granular cytoplasmic staining positive cells, and negative (low/no) those with weak or non-existent staining positive cells. Each examined core and routine paraffin block contained a minimum of 200 tumor cells.

| Table 1 Clinico-pathologic characteristics and MYCN amplification of study population |
|---------------------------------|----------------|----------------|
| Patients (n = 44)               | %              | MYCN amp      |
| Gender                         |               | No-amp        |
| Male (21)                      | 48            | 3             | 12            |
| Female (23)                    | 52            | 5             | 13            |
| Age at diagnosis (months)      |               |               |
| < 18 (29)                      | 66            | 3             | 20            |
| > 18 (15)                      | 34            | 5             | 5             |
| Risk                           |               |               |
| Intermediate, high (23)        | 52            | 8             | 10            |
| Low (21)                       | 48            | 8             | 0             |
| Stage                          |               |               |
| Metastatic (12)                | 27            | 6             | 4             |
| Non-metastatic (32)            | 73            | 2             | 21            |
| Survival                       |               |               |
| Dead (10)                      | 23            | 1             | 1             |
| Alive (34)                     | 77            | 3             | 24            |

Note that information on MYCN amplification is not available for all samples. Significant p values (p < 0.05) are in bold.
upon RA treatment [39–41]. Cell differentiation was induced by adding 10 μM all-trans retinoic acid (RA) (Sigma) to the cultures, followed by 10 days incubation (media was changed after 5 days).

mRNA isolation and RT-qPCR

RT-qPCR was performed using RNA from SH-SY5Y, SMS-KCNR, and IMR-32 cells treated or not with RA, using the IllustraRNASpin mini purification kit (GE Healthcare Life Sciences). 1 μg of total RNA was reverse transcribed using RevertAidTM reverse transcriptase, oligo (dT)18 primers, and RiboLock and RNase inhibitor (all from Fermentas). qPCR was performed as previously described [42] using validated primer sets (Qiagen) specific for the classical PTPs and reference gene (hypoxanthine phosphoribosyltransferase 1 [HPRT1]). All quantifications were normalized to the HPRT1 reference gene data. Relative quantification was performed using the comparative ΔΔCt method. Significant up-regulation or down-regulation was considered with a threshold of 2 or −2 fold change (Log2 scale), respectively. Non-significant up-regulation or down-regulation was considered between 1 and 2 fold change or between −1 and −2 fold change, respectively. Those classical PTPs displaying coordinated significant increases in the three cell lines were considered as PTPs with significant up-regulation, whereas those PTPs displaying coordinated significant changes in two cell lines and non-significant changes in one cell line were considered as PTPs with significant up-regulation or down-regulation trends.

PTPN1 knock-down, MTS cell proliferation and immunoblot assays

PTPN1 knock-down was performed by transfection of specific siRNAs using Lipofectamine 3000 (Thermo Fisher) or PepMute (SignaGen) reagents following manufacturer’s protocol. PTPNI siRNAs (siPTPN1 #1, SI00043827; siPTPN1 #2, SI00043806) were from Qiagen, and siNS (non-specific) and siGAPDH siRNAs were from Ambion. PTPNI knock-down was verified 72 h post-transfection at mRNA level by isolation of RNA and RT-qPCR as described above. Cell proliferation was analyzed 72 h post-transfection using CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) (Promega) following manufacturer’s protocol. For immunoblot analysis, SH-SY5Y cells were incubated in the presence of epidermal growth factor (EGF; 50 ng/ml) for 5 min, and whole cell protein extracts were prepared by cell lysis in ice-cold M-PER™ lysis buffer (ThermoFisher Scientific) supplemented with PhosSTOP phosphatase inhibitor and cOmplete protease inhibitor cocktails (Roche, Switzerland), followed by centrifugation at 15200g for 10 min and collection of the supernatant. Proteins (50 μg) were resolved in 10% SDS-PAGE under reducing conditions and transferred to PVDF membranes (Merck Millipore). Immunoblotting was performed using antiphosphotyrosine 4G10 (1/1000, 05–321, Merck Millipore) and anti-GAPDH (1/1000, sc-32,233, Santa Cruz Biotechnology) antibodies, followed by IRDye secondary antibody (LI-COR) and visualization by Odyssey® CLx Imaging System. Electrophoretic bands were quantified using ImageJ software.

Statistical analysis of immunohistochemistry data

Statistical analysis was performed using IBM SPSS Statistics package, and we performed crosstabs Pearson Chi square analysis, using 2-sided asymptotic Significance to calculate p-values, and interval by interval symmetric measures for Pearson’s R value.

Results

PTPN1 knock-down and growth of NB cells

To investigate the impact of the expression of PTPNI in the modulation of growth of human NB cells, SH-SY5Y cells were transiently transfected with specific siRNAs targeting PTPNI for down-regulation (Fig. 1a), and phosphotyrosine content and MTS cell proliferation assays were performed 72 h after transfection. As shown, EGF short-term stimulation triggered tyrosine phosphorylation in SH-SY5Y cells, which was enhanced upon PTPNI silencing, when compared to non-specific silencing conditions (Fig. 1b). Accordingly, siRNA down-regulation of PTPNI expression resulted in increased cell proliferation (Fig. 1c). These results suggest a linkage between tyrosine phosphorylation status and proliferation of SH-SY5Y cells and illustrate the involvement of PTPNI in the regulation of cell signaling and growth in NB.

PTPN1 expression in human NB cells and NB tumor samples

The expression patterns of PTPNI in human NB cells and NB tumor samples was investigated, in comparison with other PTPs, including PTPRH, PTPRZ1, and PTEN. The mRNA expression of these PTPs in the human adrenal gland (the major neuroendocrine tissue source of NB) and in the SH-SY5Y human NB cell line (the more studied human NB cell line) is shown in Fig. 2a and b, respectively. PTPNI mRNA is abundantly detected from both of these sources, whereas other PTP mRNA, such as PTPRZ1, are not detected. We also explored the potential role of these PTPs in NB differentiation, performing a quantitative RT-PCR (RT-qPCR) analysis of their mRNA expression on human NB cell lines differentiated in the presence of all-trans RA. These included SH-SY5Y, SMS-KCNR, and IMR-32 cell lines, which show
different genetic backgrounds in terms of ALK mutational status and MYCN amplification. The cell lines were grown in the absence or in the presence of RA for 10 days, and mRNA was isolated and subjected to RT-qPCR using specific PTP oligonucleotide primers [42]. Figure 2 shows the relative changes of PTP mRNA expression from RA-treated cells in comparison with untreated cells. PTPN1 expression was not altered upon RA cell treatment, whereas the expression of PTPRH and PTPRZ1 was significantly upregulated, and that of PTEN slightly up-regulated, in the three NB cell lines analysed.

Next, the expression on human NB tumor samples of PTPN1, PTPRH, PTPRZ1, and PTEN was analyzed by IHC using specific antibodies. A summary of our IHC results is shown in Table 2, and illustrative NB immunostained sections are shown in Fig. 3. PTPRH and PTPRZ1 were expressed in a large number of NB tumor samples, mostly displaying a cytoplasmic granular staining pattern. PTPRZ1 was expressed with high intensity in most of the tumor samples, suggesting that it could be a good marker in NB. High staining of PTPRH associated with low risk and non-IV stage. PTEN tumor suppressor was expressed in the majority of NB tumor samples and no clinical correlations were found, in agreement with previous reports [43], indicating that the lack of PTEN is not a common driving event in NB [44]. PTPN1 was also positive or weakly positive in most of
the cases, with a cytoplasmic granular immunostaining. Importantly, high PTPN1 expression correlated with poor outcome parameters, including intermediate/high risk, metastasis and stages III/IV (Table 2). Further (Chi square) analysis revealed more significant correlations with low risk \((p = 0.001, R = -0.501)\), non-metastatic \((p = 0.042, R = -0.306)\), non-IV stage \((p = 0.003, R = -0.448)\), and non-III/non-IV stage \((p = 0.005, R = -0.420)\) for samples displaying high PTPRH and low PTPN1 expression. In conclusion, our findings suggest a differential involvement of PTPN1 and PTPRH in malignant NB progression, and argue for PTPN1 high expression as a potential surrogate marker for poor outcome NB.

Discussion

The efficacy of high-risk NB novel targeted therapies relies on a precise patient stratification based on novel genetic, epigenetic, or protein biomarkers [10, 45, 46]. In our study, we have found association of PTPN1 high expression with NB poor outcome, as indicated by PTPN1 enrichment in metastatic disease, and in samples from high stage and intermediate/high-risk NB patients. Interestingly, PTPRH expression displayed inverse clinical correlations than PTPN1 expression, which were increased when PTPRH high and PTPN1 low cases were clustered. This suggests PTPRH+/PTPN1- immunostaining of NB tumors as a good molecular predictor of low risk NB. Leptin or insulin treatment induced PTPN1 mRNA expression in SH-SY5Y cells [47]. However, PTPN1 mRNA expression did not display significant changes upon RA-induced differentiation of human NB cells (this report). On the other hand, high expression of PTPRH and PTPRZ1, which were coordinately up-regulated by RA in NB cell lines, was detected in our set of NB

---

**Fig. 2**

**a** mRNA expression of PTPs in Adrenal gland. Data from GTEx (Genotype-Tissue Expression) data sets. **b** mRNA expression of PTPs in SH-SY5Y cells. Data from HPA (Human Protein Atlas). Data in **a** and **b** are reported as transcription expression NX values (Normalized eXpression data, and is based on RNA-seq data), according to https://www.proteinatlas.org/. **c** mRNA expression analysis of PTPs from human NB cell lines treated with RA. Cell lines were kept untreated or were treated for 10 days with RA, mRNA was extracted and RT-qPCR was performed using specific PTP primers. Relative mRNA expression values are shown in Log2, as fold change \pm S.D. of treated cells versus untreated cells, from at least two independent experiments. Mean fold change above 2 or below −2 was considered significant.
tumors. Interestingly, up-regulation of PTPRH has also been detected in breast cancer cell lines grown upon differentiation conditions [48]. How these PTP expression patterns in NB cells could be related with the differential expression and function of PTPs in NB tumors deserves further investigation. Noticeably, siRNA knock-down of PTPN1 resulted in increased tyrosine phosphorylation and cell proliferation of SH-SY5Y cells, indicating that PTPN1 could be important in regulating NB cell growth. This is in agreement with the report from Ozek et al. showing that PTPN1 inhibition increased the tyrosine phosphorylation and downstream signaling of TrkB, as well as the neurite outgrowth, in SH-SY5Y cells [49]. In addition, PTPN1 has been proposed to dephosphorylate the intracellular pools of ALK in mouse fibroblasts [50]. Together, our findings suggest that PTPN1 high expression in NB tumors might not be necessary for NB cell transformation, but rather could arise as a surrogate marker of NB tumor evolution, and support the hypothesis that PTPN1 growth-modulatory activity in SH-SY5Y NB cells takes place upstream in tyrosine phosphorylation signaling pathways. Further work is granted to understand the involvement of PTPN1 in NB cells growth and to validate PTPN1 as a novel NB prognostic biomarker.

Table 2 Immunostaining of PTPs from NB tissue sections

| Patients (n = 44) | % | PTPN1 | PTPRH | PTPRZ1 | PTEN |
|------------------|---|-------|-------|--------|------|
|                  |   | high  | low/no| high   | low/no| high  | low/no| high   | low/no|
| Gender           |   |       |       |        |       |       |       |        |       |
| Male (21)        | 48| 8     | 11    | 17     | 3     | 17    | 3     | 19     | 2     |
| Female (23)      | 52| 6     | 16    | 18     | 5     | 19    | 4     | 19     | 4     |
| Age at diagnosis (months) | |       |       |        |       |       |       |        |       |
| < 18 (29)        | 66| 9     | 19    | 25     | 4     | 25    | 4     | 26     | 3     |
| > 18 (15)        | 34| 8     | 5     | 10     | 4     | 11    | 3     | 12     | 3     |
| MYCN             |   |       |       |        |       |       |       |        |       |
| Amplified (8)    | 18| 4     | 3     | 5      | 3     | 6     | 0     | 7      | 1     |
| Non-amplified (25)| 57| 8     | 16    | 22     | 3     | 22    | 3     | 22     | 3     |
| Risk             |   |       |       |        |       |       |       |        |       |
| Intermediate, high(23) | 52| 10    | 11    | 15     | 7     | 17    | 5     | 19     | 4     |
| Low (21)         | 48| 3     | 17    | 20     | 1     | 2     | 19    | 19     | 2     |
| Stage            |   |       |       |        |       |       |       |        |       |
| Metastatic (12)  | 27| 6     | 4     | 7      | 4     | 9     | 3     | 11     | 1     |
| Non-metastatic (32)| 73| 8     | 23    | 28     | 4     | 27    | 4     | 27     | 5     |
| Stage            |   |       |       |        |       |       |       |        |       |
| III, IV (17)     | 39| 9     | 6     | 11     | 5     | 13    | 3     | 16     | 1     |
| non-III, non-IV (27)| 61| 5     | 21    | 24     | 3     | 23    | 4     | 22     | 5     |
| Stage            |   |       |       |        |       |       |       |        |       |
| IV (13)          | 30| 6     | 5     | 6      | 6     | 8     | 4     | 11     | 2     |
| non-IV (31)      | 70| 8     | 22    | 29     | 2     | 28    | 3     | 27     | 4     |
| Survival         |   |       |       |        |       |       |       |        |       |
| Dead (10)        | 23| 3     | 5     | 6      | 3     | 6     | 3     | 8      | 2     |
| Alive (34)       | 77| 11    | 22    | 29     | 5     | 30    | 4     | 30     | 4     |

PTP immunostaining was not obtained in some cases due to lack of tissue to perform the analysis or to non-informative immunostaining results. Significant p values (p < 0.05) are in bold.
**PTPN1 low**  
**PTPN1 high**  
**PTPRH low**  
**PTPRH high**  
**PTEN**  
**PTPRZ1**

**Fig. 3** Immunostaining of PTPs from NB tissue sections. Representative PTPN1, PTPRH, PTPRZ1, and PTEN immunostaining patterns are shown. In the case of PTPN1 and PTPRH, selected images of low and high immunoreactivity are shown (magnification: X100)

**Conclusion**

PTPN1 high expression in NB tumors associated with patient poor outcome, and PTPN1 knock-down affected the tyrosine phosphorylation status and proliferation of NB cells. This makes PTPN1 a suitable candidate for NB prognostic and intervention marker.

**Abbreviations**

IHC: Immunohistochemistry; NB: Neuroblastoma; PTK: Protein tyrosine kinase; PTP: Protein tyrosine phosphatase; RA: Retinoic acid; RTK: Receptor tyrosine kinase; TMA: Tissue microarray

**Acknowledgements**

We thank Basque Country Biobank for help and support, and Arantza Perez Dobaran (Department of Physiology, Universidad del País Vasco, UPV/EHU, Leioa, Bizkaia, Spain) for expert technical assistance.

**Authors’ contributions**

CENX, OA, LZ, RL, JC, JIL, and RP conceived and designed the experimental analysis. CENX, OA, and LZ performed the experiments and collected data. CENX, OA, LZ, RLA, AE, JC, JIL, and RP contributed materials and analysis tools, and interpreted data. CENX and RP wrote the paper. All authors read and approved the final manuscript.

**Funding**

This work was partially supported by grants: BIO13/C0I/001/BC from BIOEF (EITB maratoia), Basque Country, Spain; SAF2013–48812-R and SAF2016–79847-R from Ministerio de Educación y Ciencia (to RP) and Ministerio de Economía y Competitividad (Spain and Fondo Europeo de Desarrollo Regional) (to RP and JIL); and 239813 from The Research Council of Norway (to CENX). AE was supported by a predoctoral grant from the Basque Government (Programa de Formación de Personal Investigador no doctor, Departamento de Educación, Política Lingüística y Cultura del Gobierno Vasco).

**Availability of data and materials**

All data generated or analysed during this study are included in this published article.

**Ethics approval and consent to participate**

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Ethical and Scientific Committees of the Basque Country Public Health System, Osakidetza, INC + CES BIOEF2015–03) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Biomarkers in Cancer Unit, Biocruces Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain. 2Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, P.O. Box 4950 Nydalen, N-0424 Oslo, Norway. 3Department of Pathology, Cruces University Hospital, University of the Basque Country (UPV/EHU), Barakaldo, Bizkaia, Spain. 4Pediatric Oncology and Hematology, Cruces University Hospital, Barakaldo, Bizkaia, Spain. 5Quantitative Biomedicine Unit, Biocruces Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain. 6IKERBASQUE, Basque Foundation for Science, Bilbao, Spain. 7Biocruces Bizkaia Health Research Institute, Hospital Universitario de Cruces, Plaza Cruces s/n, 48903 Barakaldo, Spain.

Received: 15 October 2019 Accepted: 6 December 2019

**Published online:** 14 December 2019

**References**

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007; 369(9579):2106–20.
2. Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA. Neuroblastoma. Nat Rev Dis Primers. 2016;2:16078.
3. Tsujita S, Kodama S. Identification of the primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014; 32(28):3169–76.
4. Brodeur GM. Spontaneous regression of neuroblastoma. Cell Tissue Res. 2018;372(2):227–38.
5. Mohlin SA, Wigerup C, Pahlman S. Neuroblastoma aggressiveness in relation to sympathetic neuronal differentiation stage. Semin Cancer Biol. 2011;21(4): 276–82.
6. Cole KA, Maris JM. New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clin Cancer Res. 2012;18(9):2423–8.
7. Smith V, Foster J. High-Risk Neuroblastoma Treatment Review. Children. 2018;5(9).
8. Amoroso L, Hautp L, Garaventa A, Ponzoni M. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma. Expert Opin Investig Drugs. 2017;26(11):1281–93.
9. Berlanga P, Canete A, Castel V. Advances in emerging drugs for the treatment of neuroblastoma. Expert Opin Emerg Drugs. 2017;22(1):63–75.
10. Cheung BB. Combination therapies improve the anticancer activities of retinoids in neuroblastoma. World J Clin Oncol. 2015;6(6):212–5.
11. Zage PE. Novel Therapies for Relapsed and Refractory Neuroblastoma. Children. 2018;5(11).
13. Hunter T. The genesis of tyrosine phosphorylation. Cold Spring Harb Perspect Biol. 2014;6(5):a020644.
14. Ogawa S, Takita J, Sanada M, Hayashi Y. Oncogenic mutations of ALK in neuroblastoma. Cancer Sci. 2011;102(3):302–8.
15. Ritenour LE, Randall MP, Bosse KR, Diskin SJ. Genetic susceptibility to neuroblastoma: current knowledge and future directions. Cell Tissue Res. 2018;372(2):287–307.
16. Trigg RM, Turner SD. ALK in Neuroblastoma: Biological and Therapeutic Implications. Cancers. 2018;10(4).
17. Carpenter EL, Mosse YP. Targeting ALK in neuroblastoma—preclinical and clinical advancements. Nat Rev Clin Oncol. 2012;9(7):391–9.
18. Janoueix-Lerosey I, Lopez-Delisle L, Delattre O, Rohrer H. The ALK receptor tyrosine phosphatases. Methods Mol Biol. 2016;1447:1–14.
19. Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell. 2012;22(1):117–30.
20. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoeben J, Van Maerken T, et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res. 2010;16(17):4353–62.
21. Biodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, Light JE, Kolla V, Evans AE. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 2009;15(10):3244–50.
22. Croucher JL, Iyer R, Li N, Molteni V, Lorenz J, Gordon WP, Tuntland T, Liu B, Biodeur GM. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts. Cancer Chemother Pharmacol. 2015;75(1):131–41.
23. Alonso A, Nunes-Xavier CE, Bayon Y, Pulido R. The extended family of protein tyrosine phosphatases. Methods Mol Biol. 2016;1447:1–23.
24. Hale AJ, Ter Steege E, den Hertog J. Recent advances in understanding the role of protein-tyrosine phosphatases in development and neurodegeneration. Front Mol Neurosci. 2017;10:282–93.
25. Hendriks WJ, Elson A, Harroch S, Pulido R, Stoker A, den Hertog J. Protein tyrosine phosphatases in health and disease. FEBS J. 2013;280(2):708–30.
26. Hendriks WJ, Pulido R. Protein tyrosine phosphatase variants in human hereditary disorders and disease susceptibilities. Biochim Biophys Acta. 2013;1832(10):1673–95.
27. Tonks NK. Protein tyrosine phosphatases—from housekeeping enzymes to master regulators of signal transduction. FEBS J. 2013;280(2):346–78.
28. Clark O, Daga S, Stoker AW. Tyrosine phosphatase inhibitors combined with retinoic acid can enhance differentiation of neuroblastoma cells and trigger ERK- and AKT-dependent, p53-independent senescence. Cancer Lett. 2013;328(1):44–54.
29. Clark O, Park I, Di Florio A, Cichon AC, Rustin S, Juvor R, Maeshima R, Stoker AW. Oxovanadium-based inhibitors can drive redox-sensitive cytotoxicity in neuroblastoma cells and synergise strongly with buthionine sulfoximine. Cancer Lett. 2015;375(1):316–27.
30. Feldhammer M, Uetani N, Miranda-Saavedra D, Tremblay ML. PTP1B: a simple enzyme for a complex world. Crit Rev Biochem Mol Biol. 2014;48(5):430–45.
31. Tonks NK. PTP1B: from the sidelines to the front lines! FEBS Lett. 2003;546(1):140–8.
32. Yip SC, Saha S, Chemoff J. PTP1B: a double agent in metabolism and oncogenesis. Trends Biochem Sci. 2010;35(8):442–9.
33. Zhang S, Zhang Zy. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discov Today. 2007;12(9–10):373–81.
34. Chein Q, Li Y, Li Z, Zhao Q, Fan L. Overexpression of PTP1B in human colorectal cancer and its association with tumor progression and prognosis. J Mol Histol. 2014;45(2):153–9.
35. Julien SG, Dube N, Read M, Penney J, Paquet M, Han Y, Kennedy BP, Muller WJ, Tremblay ML. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat Genet. 2007;39(3):338–46.
36. Liu H, Wu Y, Zhu S, Liang W, Wang Z, Wang Y, Lu T, Yao Y, Yuan D, Song Y. PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer. Cancer Lett. 2015;359(2):218–25.
37. Wang N, She J, Liu W, Shi J, Yang Q, Shi B, Hou P. Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients. Cell Cycle. 2015;14(5):732–43.
38. Aurentenx O, Zaldumbide L, Erramuspe A, Lopez R, Lopez JI, Cortes JM, Pulido R, Nunes-Xavier CE. DUSP5 expression associates with poor prognosis in human neuroblastoma. Exp Mol Pathol. 2018;105(3):272–8.
39. Gaetano C, Matsumoto K, Thiele CJ. In vitro activation of distinct molecular and cellular phenotypes after induction of differentiation in a human neuroblastoma cell line. Cancer Res. 1992;52(16):4402–7.
40. Pahlman S, Ruasala AI, Abrahamsson L, Mattsson ME, Esscher T. Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation. Cell Differ. 1984;14(2):135–44.
41. Sidell N, Altman A, Haussler MR, Seeger RC. Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res. 1983;148(1):21–30.
42. Nunes-Xavier CE, Pulido R. Global RT-PCR and RT-qPCR analysis of the mRNA expression of the human PTP1B. Mol Biol. 2016;1447:25–37.
43. Izycka-Swieszewska E, Drozynska E, Reepko R, Kobierska-Gulda G, Grajekowska W, Perek D, Balcerska A. Analysis of PI3K/AKT/mTOR signalling pathway in high risk neuroblastic tumours. Pol J Pathol. 2010;61(4):192–8.
44. Munoz J, Lazza C, Inda MM, Nistal M, Pestaña A, Encio U, Castreñas JS. Homozygous deletion and expression of PTEN and DMBT1 in human primary neuroblastoma and cell lines. Int J Cancer. 2004;109(5):673–9.
45. Ahmed AA, Zhang L, Reddwalla N, Hetherington M. Neuroblastoma in children: update on clinicopathologic and genetic prognostic factors. Pediatr Hematol Oncol. 2017;34(3):165–85.
46. Bagatell R, Cohn SL. Genetic discoveries and treatment advances in neuroblastoma. Curr Opin Pediatr. 2016;28(1):19–25.
47. Benomar Y, Berthou F, Vacher CM, Baleux V, Gertler A, Dijane J, Taouis M. Leptin but not ciliary neurotrophic factor (CNTF) induces phosphotyrosine phosphatase-1B expression in human neuronal cells (SH-SY5Y): putative explanation of CNTF efficiency in leptin-resistant state. Endocrinology. 2009;150(3):1182–91.
48. Nunes-Xavier CE, Elson A, Pulido R. Epidermal growth factor receptor (EGFR)-mediated positive feedback of protein-tyrosine phosphatase epsilon (PTPepsilon) on ERK1/2 and AKT protein pathways is required for survival of EGFR-mediated positive feedback of protein-tyrosine phosphatase epsilon (PTPepsilon) on ERK1/2 and AKT protein pathways is required for survival of human breast cancer cells. J Biol Chem. 2012;287(5):3433–44.
49. Ozok C, Kanosi SE, Zhang ZY, Grill HJ, Bence KK. Protein-tyrosine phosphatase 1B (PTP1B) is a novel regulator of central brain-derived neurotrophic factor and tropomyosin receptor kinase B (TrkB) signaling. J Biol Chem. 2014;289(46):31682–92.
50. Bouterin MC, Mazot P, Faure C, Doly S, Gervasi N, Tremblay ML, Vigny M. Control of ALK (wild type and mutated forms) phosphorylation: specific role of the phosphatase PTP1B. Cell Signal. 2013;25(6):1505–13.